Browse
Log in / Register
Share
Updated September 30, 2026
Currus Biologics has received U.S. Food and Drug Administration clearance to take its lead CAR-T therapy, CUR-001, into a first-in-human Phase 1 trial. The study will enroll patients with mesothelin-positive advanced refractory solid tumors, and the Melbourne-based company expects to dose the first patient in early 2027.
The clearance marks the first clinical step for Currus's BEAT platform, a bispecific antibody approach designed to overcome one of the biggest obstacles in cancer immunotherapy: the limited effectiveness of CAR-T cells against solid tumors.
CAR-T cell therapy has delivered durable remissions in several blood cancers, including aggressive lymphomas and multiple myeloma. But solid tumors have remained a much harder target. Unlike blood cancers, solid tumors create a hostile microenvironment that actively suppresses T cells and pushes them toward exhaustion before they can mount a sustained attack.
Tumors also present physical and biochemical barriers. Dense stromal tissue can block CAR-T cells from reaching the tumor core, while suppressive immune cells, regulatory T cells, and inhibitory cytokines further blunt the antitumor response. These are the biological reasons why the success seen in liquid tumors has not yet extended to the roughly 90% of cancers that are solid tumors.
CUR-001 combines two components. CURT-001 is an autologous CAR-T cell product engineered to target mesothelin, a protein expressed at high levels in several hard-to-treat cancers. Because it is autologous, each patient's own cells are collected, engineered, expanded, and infused back. CURB-001 is the BEAT component, a bispecific antibody designed to bring the CAR-T cells together with the patient's professional antigen-presenting cells.
The hypothesis behind BEAT is that activation should happen earlier and in a more favorable environment. Rather than relying on the tumor itself to provide the activating signal—where the microenvironment is already hostile—the BEAT antibody is intended to create a productive immune priming event, likely in lymphoid tissue. Preclinical data from Currus suggest the combination improves CAR-T expansion, persistence, and tumor infiltration. The company also reports epitope spreading, meaning the immune response may broaden to additional tumor antigens, and immunologic memory, which could support longer-lasting responses.
The mesothelin target is particularly relevant for a basket trial. Mesothelin is overexpressed in conditions such as mesothelioma, pancreatic cancer, ovarian cancer, and some lung cancers. A basket design allows the study to enroll patients across multiple tumor types that share the target, rather than limiting the trial to a single cancer indication.
The open-label Phase 1 basket trial is designed primarily to assess safety, tolerability, and pharmacology. Early signals of antitumor activity will also be captured, especially as dose escalation progresses. In a first-in-human cell therapy study, dose escalation tends to be cautious, with close monitoring for infusion-related reactions and unexpected toxicities.
Currus has not yet disclosed trial sites or detailed enrollment criteria beyond the mesothelin-positive and advanced refractory requirements. More concrete information is expected when the trial appears in the ClinicalTrials.gov registry. The early-2027 first-patient target suggests that site selection, manufacturing logistics, and protocol activation are still being finalized.
Autologous CAR-T trials come with operational complexity. Every patient's product is made individually, and vein-to-vein time can vary. Manufacturing failures, supply delays, or patient progression before infusion are all risks that have affected other CAR-T developers. Despite these challenges, the field has matured considerably, and many academic and commercial centers now have established CAR-T manufacturing workflows.
One aspect that distinguishes CUR-001 from a conventional single-target CAR-T program is the platform claim. Currus says BEAT is designed to be compatible with essentially any CAR-T format and any tumor target. If the mechanism is validated in humans, BEAT could become an add-on technology for other developers that have strong CAR-T products but limited solid-tumor activity.
The company says its preclinical work has been supported by independent academic validation. That is important in a field where animal-model results have frequently failed to predict clinical outcomes in solid tumors. Peer-reviewed publication of the preclinical findings would offer an additional layer of confidence for outside observers.
No CAR-T product has received FDA approval for a solid-tumor indication as of this writing. Many developers have attempted to improve CAR-T cells in solid tumors by adding costimulatory domains, knocking out exhaustion-related genes, or delivering cells directly into the tumor. Some approaches have shown encouraging early signals, but none has produced a broadly accepted standard of care.
Currus's BEAT strategy is distinct because it focuses on the activation step. The bispecific engager reconnects the CAR-T cells with antigen-presenting cells, effectively rewriting the immune activation circuit before CAR-T cells encounter the tumor microenvironment. That is a different mechanism from simply arming the CAR-T cell with additional signaling domains.
The company's emphasis on a basket design is also practical. Mesothelin-positive solid tumors span multiple disease areas, and a basket trial can provide a cross-indication signal from a relatively small study. That may make it easier to identify which tumor types are most likely to respond, assuming the safety profile is acceptable.
Currus CEO Sam Cobb described the FDA clearance as a major milestone for the company and an important step toward bringing BEAT into the clinic. Board chair Alessandra Cesano acknowledged that mesothelin has long been viewed as an attractive CAR-T target in solid tumors, but durable antitumor activity has remained elusive. Chief medical officer Swami Murugappan emphasized the need to evaluate safety, pharmacology, and early clinical activity in patients with advanced disease.
Currus Biologics is an Australian biotech specializing in cell therapy and cancer immunotherapy. The company is backed by Brandon Capital Partners, Main Sequence Ventures, and Uniseed, a group of Australian investors that have supported the development of multiple life sciences companies. Currus is developing the BEAT platform as a universal, cost-effective add-on to existing and future CAR-T products.
FDA clearance of the CUR-001 IND moves Currus Biologics into a critical testing phase. The next major milestone is the first patient dose, expected in early 2027. After that, initial safety and efficacy observations will provide an early indication of whether the BEAT mechanism can do in humans what it has done in preclinical models. If the results are favorable, CUR-001 may represent one of the more important attempts to finally make CAR-T therapy work against solid tumors.
